LUMIFY Drug Patent Profile
✉ Email this page to a colleague
When do Lumify patents expire, and what generic alternatives are available?
Lumify is a drug marketed by Bausch And Lomb Inc and is included in two NDAs. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has thirty-seven patent family members in sixteen countries.
The generic ingredient in LUMIFY is brimonidine tartrate. There are eleven drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lumify
A generic version of LUMIFY was approved as brimonidine tartrate by BAUSCH AND LOMB on May 28th, 2003.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LUMIFY?
- What are the global sales for LUMIFY?
- What is Average Wholesale Price for LUMIFY?
Summary for LUMIFY
| International Patents: | 37 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 76 |
| Clinical Trials: | 6 |
| Patent Applications: | 330 |
| Drug Prices: | Drug price information for LUMIFY |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LUMIFY |
| DailyMed Link: | LUMIFY at DailyMed |
Recent Clinical Trials for LUMIFY
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Tulane University | Phase 4 |
| University of Louisville | Phase 4 |
| Bausch & Lomb Incorporated | Phase 3 |
Pharmacology for LUMIFY
| Drug Class | alpha-Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha-Agonists |
Paragraph IV (Patent) Challenges for LUMIFY
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| LUMIFY | Ophthalmic Solution | brimonidine tartrate | 0.025% | 208144 | 1 | 2021-07-12 |
US Patents and Regulatory Information for LUMIFY
LUMIFY is protected by four US patents.
Patents protecting LUMIFY
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
Preferential vasoconstriction compositions and methods of use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
Compositions and methods for eye whitening
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | LUMIFY | brimonidine tartrate | SOLUTION/DROPS;OPHTHALMIC | 208144-001 | Dec 22, 2017 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bausch And Lomb Inc | LUMIFY PRESERVATIVE FREE | brimonidine tartrate | SOLUTION/DROPS;OPHTHALMIC | 218424-001 | Apr 19, 2024 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bausch And Lomb Inc | LUMIFY | brimonidine tartrate | SOLUTION/DROPS;OPHTHALMIC | 208144-001 | Dec 22, 2017 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bausch And Lomb Inc | LUMIFY | brimonidine tartrate | SOLUTION/DROPS;OPHTHALMIC | 208144-001 | Dec 22, 2017 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bausch And Lomb Inc | LUMIFY | brimonidine tartrate | SOLUTION/DROPS;OPHTHALMIC | 208144-001 | Dec 22, 2017 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bausch And Lomb Inc | LUMIFY PRESERVATIVE FREE | brimonidine tartrate | SOLUTION/DROPS;OPHTHALMIC | 218424-001 | Apr 19, 2024 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bausch And Lomb Inc | LUMIFY PRESERVATIVE FREE | brimonidine tartrate | SOLUTION/DROPS;OPHTHALMIC | 218424-001 | Apr 19, 2024 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LUMIFY
See the table below for patents covering LUMIFY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 2696874 | COMPOSITIONS ET MÉTHODES UTILISÉES DE TRAITEMENT D'AFFECTIONS NASALES (COMPOSITIONS AND METHODS FOR THE TREATMENT OF NASAL CONDITIONS) | ⤷ Sign Up |
| Russian Federation | 2016111112 | КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ ЛЕЧЕНИЯ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ НОСА | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2010014552 | ⤷ Sign Up | |
| Japan | 2013514985 | ⤷ Sign Up | |
| Denmark | 2320911 | ⤷ Sign Up | |
| Japan | 5671459 | ⤷ Sign Up | |
| South Korea | 20120128610 | COMPOSITIONS AND METHODS FOR EYE WHITENING | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LUMIFY
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1631293 | 92462 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225 |
| 1631293 | 2014C/042 | Belgium | ⤷ Sign Up | PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221 |
| 1631293 | 2014/041 | Ireland | ⤷ Sign Up | PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221 |
| 1631293 | C300683 | Netherlands | ⤷ Sign Up | PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
| 1631293 | 14C0056 | France | ⤷ Sign Up | PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
| 1631293 | 300683 | Netherlands | ⤷ Sign Up | PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
